Gilead Sciences, Inc.

Kirk L Stevens

Christopher T Clark

Gary Bruce Phillips

Musong Kim

William John Watkins

Leena Patel

John O Link

Kevin S Currie

Peter A Blomgren

Jeffrey E Kropf

Sheila M Zipfel

Jennifer Anne Treiberg

Zhongdong Zhao

Jayaraman Chandrasekhar

Suet Chung Yeung

Stephane Perreault

James G Taylor

Yasamin Moazami

Jason K Perry

Natalie Seeger

Taryn Campbell

Nicole Nava

Jeromy J Cottell

Elizabeth M Bacon

Scott D Schroeder

Thorsten A Kirschberg

Nathan E Wright

Joshua A Kaplan

Neil H Squires

Julian Andrew Codelli

Gayatri Balan

Chien-Hung Chou

Kassandra F Sedillo

Zhimin Du

Jeff A Zablocki

Hyung-Jung Pyun

Devan Naduthambi

Adam James Schrier

Jennifer R Lo

Lafe J Purvis, Ii

Shaopei Cai

Julian A Codelli

Suet C Yeung

Scott A Mitchell

Chandrasekar Venkataramani

Scott E Lazerwith

Zheng-Yu Yang

Darryl Kato

Barton W Phillips

Jianjun Xu

Gregory Notte

Seung H Lee

Juan A Guerrero

Jerry B Evarts

Jiayao Li

Aaron C Schmitt

Michael Sangi

Ashley Anne Katana

Joshua J Van Veldhuizen

Julie Farand

Marcin Stasiak

William Baker

Josh Van Veldhuizen

Nicholas Mai

Petr Jansa

Randall W Vivian

Kapil Kumar Karki

Daniel H Byun

Jennifer Alissa Loyer-Drew

Jin-Ming Xiong

Kyla Bjornson

Zachary A Kasun

Megan E Neubig

Nathaniel H Stanley

JinMing Xiong

James L Bachman

Gary Phillips

Stephane Perrault

Lafe J Ii Purvis

Kapil K Karki

Jinming Xiong

Compounds of formula: wherein the variable substituents are defined herein.

KHK inhibitors

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Quinoline derivatives

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Cot modulators and methods of use thereof

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

Compounds for inhibition of &#x3b1;4 &#x3b2;7 integrin

Compounds for inhibition of alpha 4 beta 7 integrin

Compounds for inhibition of &#x3b1;4&#x3b2;7 integrin

Imidazopyridine derivatives

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A', B&#x2032;, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Phosphatidylinositol 3-kinase inhibitors

COT modulators and methods of use thereof

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A', W, W, W, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, X, X, R, R, R, R, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Syk inhibitors

Growing community of inventors

Bothell, WA, United States of America

Kirk L Stevens